Empasug -M 500/12.5

Description:

• Empasug-M 500/12.5 combines empagliflozin (12.5 mg) and metformin (500 mg), offering enhanced glycemic control for patients inadequately managed with lower doses. The formulation targets multiple pathophysiological factors in T2DM and is suitable for long-term metabolic management.
• Recognized among trusted empagliflozin tablet manufacturers, we ensure high-purity ingredients and stringent process controls.
• As a leading empagliflozin tablets manufacturing company, we uphold global standards across formulation, quality assurance, and compliance.
• We also serve as a reliable empagliflozin tablet exporter, supporting international markets with consistent supply and documentation.
• Our footprint as a premium empagliflozin tablet supplier is well-established among healthcare institutions and B2B partners.

Key Features:

• Provides stronger SGLT2 inhibition for superior glucose excretion
• Complements metformin’s insulin-sensitizing effects
• Contributes to HbA1c reduction, weight control, and blood pressure lowering
• Demonstrates renal and cardiovascular support in real-world settings
• Enables once-daily therapy with high patient acceptance

Usage Guidelines:

• Administer with food to minimize gastrointestinal adverse reactions
• Suitable for patients needing step-up dual therapy from 500/5 formulation
• Ensure renal assessment before and during therapy

Safety Profile:

• Side effects may include nausea, polyuria, or UTIs
• Avoid in patients with severe hepatic/renal impairment
• Not indicated for type 1 diabetes mellitus or ketoacidosis

Uses / Indications: Used in adults with type 2 diabetes mellitus (T2DM) to improve blood sugar control as an adjunct to diet and exercise. Combines SGLT2 inhibitor (Empagliflozin) and biguanide (Metformin) for dual action on glucose regulation. Not for type 1 diabetes or diabetic ketoacidosis.